Navigation Links
Sosei in Medical News

Sosei Announces Start of AD 923 Phase III Studies in Europe

...OKYO, Japan, February 12 /PRNewswire-FirstCall/ -- sosei Group Corporation ("Sosei"; TSE Mothers Index: 456...safety and tolerability of AD 923. In June 2006, sosei entered into an agreement with Mundipharma Interna...tional markets, excluding North America and Japan. sosei is currently evaluating its commercialisation opti...

Sosei Announces Approval to Start AD 923 Phase III Studies in Europe

... TOKYO, November 28 /PRNewswire-FirstCall/ -- sosei Group Corporation ("Sosei"; TSE Mothers Index: 456...in the trial". Notes to Editors: About Sosei sosei Group Corporation is a leading international bioph...ckout system that prevents inadvertent overdosing. sosei has concluded a range of studies that confirm the ...

Sosei Announces Update on Phase I Trials for SD118

... TOKYO, November 27 /PRNewswire-FirstCall/ -- sosei Group Corporation ("Sosei"; TSE Mothers Index: 456...ction that lead to improved drugs. About Sosei sosei Group Corporation is a leading international bioph...s on its lead compound NSL-043 in partnership with sosei Group Corporation, a listed Japanese biopharmaceut...

Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD

...AM, England, November 15 /PRNewswire-FirstCall/ -- sosei Group Corporation ("Sosei"; TSE Mothers Index: 456...o severe COPD. NVA237 was licensed to Novartis by sosei and Vectura in 2005 in a deal in which the two com... About the NVA237 licence agreement with Novartis sosei and its co-development partner Vectura Group plc c...
Sosei in Medical Technology

Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237

...riggers $7.5m Milestones for Both Companies sosei Group Corporation ("Sosei"; TSE Mothers Index: 456...l trigger a $7.5 million milestone payment to both sosei and Vectura. The trial is a randomised, dou... NVA237 was licensed to Novartis in April 2005 by sosei and its co-development partner Vectura. Novartis i...

Sosei Confirms the Safety of SD118 in Two Phase I Trials

... TOKYO, December 8 /PRNewswire-FirstCall/ -- sosei Group Corporation ("Sosei"; TSE Mothers Index: 456...esia A reduced sense of touch. About sosei sosei Group is a leading international biopharmaceutical...

Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting

...service provider and drug development Company, and sosei Group Corporation ("Sosei"; TSE Mothers Index: 456...nflammatory pain." Mr Shinichi Tamura, CEO sosei Group added: "We are pleased to have collaborated ...opment compound NSL-043/SD118, in partnership with sosei Co. Ltd. Both of these trials reported a successfu...

NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium

...lar findings. NVA237 was licensed to Novartis by sosei and Vectura in 2005 in a deal in which the two com...VA237 and QVA149 licence agreement with Novartis sosei and Vectura Group plc concluded a global developme...st, as QVA149. Under the terms of the agreement, sosei and Vectura to date have each received $15 million...

Sosei Announces Completion of Phase III Trial for NorLevo(R)

... TOKYO, July 10 /PRNewswire-FirstCall/ -- sosei Group Corporation ("Sosei"; TSE Mothers Index: 456...ncy contraceptive pill (ECP) SOH-075 (NorLevo(R)). sosei acquired the exclusive distribution rights to the ...d as an essential drug by the WHO. About Sosei sosei Group is a leading international biopharmaceutical...

Sosei Announces Successful Completion of AD 923 Pharmacokinetic Study in the USA

... TOKYO, May 22, 2007 /PRNewswire-FirstCall/ -- sosei Group Corporation , a biopharmaceutical company, t...with no significant safety issues identified. sosei has reached agreement with EU regulatory authoriti...o Phase III studies." Notes for Editors: About sosei ...
Sosei in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...icenses Antibody-Drug Conjugates Development Rights to Genentech II-88 National Cancer Institute Enters into Agreement with Illumina II-89 sosei Seeks Marketing Rights for Prostate Cancer Drug in Japan II-89 8. Focus on Select Global Players II-90 Abbott Laboratories (USA) II-90 Ae...

Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria

... Based on its cytokine modulatory activity, sosei were developing RS(+) mefloquine as AD 452 for the...es over existing treatment options." About sosei sosei Group is a leading international biopharmaceutical...

Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))

... TOKYO, October 22 /PRNewswire-FirstCall/ -- sosei Group Corporation ("Sosei"; TSE Mothers Index: 456...he biopharmaceutical company, today announced that sosei Co., Ltd., its wholly owned Japanese subsidiary, h... oral emergency contraceptive for post-coital use. sosei acquired the exclusive distribution rights to the ...

WWMR, Inc. Announces Launch of New Pain Clinic Monitor

...Reckitt Benckiser/Vernalis, Durect, Rinat Neuroscience/Pfizer, Elan Pharm, Roche, Eli Lilly, Sanofi-Aventis, Endo Pharm, Schwarz, Forest Laboratories, sosei R&D, Gedeon Richter, Teikoku Seiyaku, GlaxoSmithKline, TheraQuest, Grunenthal, Vernalis, GW Pharmaceuticals, Watson Pharm, Janssen-Cilag, Wyeth Pharma...

Sosei Announces Outcome of Strategy Review

... TOKYO, May 14 /PRNewswire-FirstCall/ -- sosei Group Corporation ("Sosei"; TSE Mothers Index: 456...ness from NVA237/QVA149 in a few years time. - sosei is closing its Chesterford operation and sosei R&D's continuing business will relocate to London...

Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities

... Prior to Marquant, Joy's positions included: Vice President, Business Development at Nabi Biopharmaceuticals; Vice President, Business Development at sosei Co. Ltd; Commercial Director at Xenova Group Limited; member of the Pharmaceuticals and Medical Products practice at Accenture; and various roles in t...

Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome

... TOKYO, September 18 /PRNewswire-FirstCall/ -- sosei Group Corporation ("Sosei"; TSE Mothers Index: 456... potential indications." Notes to Editors: About sosei sosei Group Corporation is a leading international bioph...
Other Tags
(Date:4/17/2015)... (PRWEB) April 17, 2015 Calvary Hospital recently ... Inc. as Executive Vice President on May 11. The Fund ... and historic mission. Barr succeeds Vincent J. Spinelli, who retired ... agreed to take on and supervise the important work that ... and CEO. “As Calvary continues to expand and bring our ...
(Date:4/17/2015)... Oxytocin is a natural hormone ... to help mothers bond to their newborn, as well ... new studies performed, at NYU Langone Medical Center in ... Medical News Today on April 16, 2015, reveals that ... behavior. The study reveals that, when oxytocin was injected ...
(Date:4/17/2015)... 17, 2015 Mario Badescu ... and perfect facial skin with its unique combination ... blend of energizing botanicals. This cushiony gel-based formula ... cause breakouts and inhibit penetration of special treatments, ... Ivory Palm Seeds, This uncommon exfoliating ingredient is ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 According to ... an estimated 50 million Americans suffer from all types ... skin and eye allergies. Thanks to comprehensive allergy testing ... ( caremedurgentcare.com ), there’s now a way to get ... weather. , “Allergy triggers, or allergens, can vary by ...
(Date:4/17/2015)... April 17, 2015 Cheapquotesautoinsurance.com has released a ... that has a salvage title . , An auto ... under a salvage title if the owner has paid for ... salvage title car is not possible, while in other states, ... released blog post provides more information on the subject. ...
Breaking Medicine News(10 mins):Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 2Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 3Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3Health News:Mario Badescu Skin Care Launches Botanical Exfoliating Scrub 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 3Health News:Compare Auto Insurance Quotes for Cars With A Salvage Title! 2
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
Other Contents